SOUTH CHINA FIN plans to partner with a third-party consortium to enter the AI pharmaceutical sector

SOUTH CHINA FIN (00619.HK) announced that it has signed a memorandum of understanding with an independent third party, with both parties intending to establish a joint venture in mainland China or Hong Kong to engage in the development of an AI drug research and development platform and provide related technical services; develop an AI efficacy prediction platform to serve global beauty clients; develop disease and aging pipelines; and develop direct-to-consumer anti-aging products